PCSK9 as predictor for recurrent cardiovascular disease in familial hypercholesterolemia

被引：2
|
作者：
Reeskamp, Laurens F. [1 ]
Tromp, Tycho R. [1 ]
Hovingh, G. Kees [1 ]
机构：
[1] Univ Amsterdam, Amsterdam UMC, Dept Vasc Med, Meibergdreef 9, NL-1105 AZ Amsterdam, Netherlands
来源：
EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY | 2021年 / 28卷 / 03期
关键词：
CALCIFICATION; STATINS; EVENTS; RISK;
D O I：
10.1177/2047487319886140
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：270 / 271
页数：2
相关论文
共 50 条
  • [21] Prevention of cardiovascular disease in patients with familial hypercholesterolaemia: The role of PCSK9 inhibitors
    Pecin, Ivan
    Hartgers, Merel L.
    Hovingh, G. Kees
    Dent, Ricardo
    Reiner, Zeljko
    EUROPEAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2017, 24 (13) : 1383 - 1401
  • [22] PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies
    El Khoury, Petra
    Elbitar, Sandy
    Ghaleb, Youmna
    Abou Khalil, Yara
    Varret, Mathilde
    Boileau, Catherine
    Abifadel, Marianne
    CURRENT ATHEROSCLEROSIS REPORTS, 2017, 19 (12)
  • [23] PCSK9 Mutations in Familial Hypercholesterolemia: from a Groundbreaking Discovery to Anti-PCSK9 Therapies
    Petra El Khoury
    Sandy Elbitar
    Youmna Ghaleb
    Yara Abou Khalil
    Mathilde Varret
    Catherine Boileau
    Marianne Abifadel
    Current Atherosclerosis Reports, 2017, 19
  • [24] A Decision Aid for the Use of PCSK9 Inhibitors in Patients With Familial Hypercholesterolemia
    Farwati, Medhat
    Shaw, Kevin
    Hargraves, Ian G.
    Montori, Victor M.
    Kullo, Iftikhar J.
    CIRCULATION, 2018, 138
  • [25] PCSK9 Inhibitors for Homozygous Familial Hypercholesterolemia Useful But Seldom Sufficient
    Thompson, Gilbert R.
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2020, 76 (02) : 143 - 145
  • [26] LIPOPROTEIN(A) IN FAMILIAL HYPERCHOLESTEROLEMIA WITH PCSK9 GAIN-OF-FUNCTION MUTATIONS
    Tada, Hayato
    Kawashiri, Masa-Aki
    Nohara, Atsushi
    Inazu, Akihiro
    Mabuchi, Hiroshi
    Yamagishi, Masakazu
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2016, 67 (13) : 1896 - 1896
  • [27] NEW GAIN OF FUNCTIONS MUTATIONS IN PCSK9 AND THEIR IMPACT IN FAMILIAL HYPERCHOLESTEROLEMIA
    AbiFadel, M.
    Rabes, J. -P.
    Guerin, M.
    Carreau, V.
    Carrie, A.
    Varret, M.
    Samson-Bouma, M. -E.
    Tosolini, L.
    Erlich, D.
    Couvert, P.
    Bonnefont-Rousselot, D.
    Bruckert, E.
    Prat, A.
    Seidah, N.
    Boileau, C.
    ATHEROSCLEROSIS SUPPLEMENTS, 2011, 12 (01) : 10 - 10
  • [28] CHARACTERIZATION OF THE EFFECTS OF FAMILIAL HYPERCHOLESTEROLEMIA MUTATIONS IN LDLR ON PCSK9 BINDING
    Deng, Shijun
    Alabi, Adekunle
    Zhang, Dawei
    ATHEROSCLEROSIS SUPPLEMENTS, 2018, 32 : 55 - 55
  • [29] How many familial hypercholesterolemia patients are eligible for PCSK9 inhibition?
    Masana, Luis
    Plana, Nuria
    Perez-Calahorra, Sofia
    Ibarretxe, Daiana
    Lamiquiz-Moneo, Itziar
    Pedro-Botet, Juan
    Suarez-Tembra, Manuel
    Valdivielso, Pedro
    Ortega, Emilio
    Civeira, Fernando
    ATHEROSCLEROSIS, 2017, 262 : 107 - 112
  • [30] Methylation status of LDLR, PCSK9 and LDLRAP1 is associated with cardiovascular events in familial hypercholesterolemia
    Marcal, Elisangela da Silva Rodrigues
    Borges, Jessica Bassani
    Bastos, Gisele Medeiros
    Hirata, Thiago Dominguez Crespo
    de Oliveira, Victor Fernandes
    Goncalves, Rodrigo Marques
    Faludi, Andre Arpad
    Franca, Joao Italo Dias
    Silva, Daiana Vitor de Oliveira
    Malaquias, Vanessa Barbosa
    Luchessi, Andre Ducati
    Silbiger, Vivian Nogueira
    Nakazone, Marcelo Arruda
    Carmo, Tayanne Silva
    Silva Souza, Doroteia Rossi
    Sampaio, Marcelo Ferraz
    Hirata, Rosario Dominguez Crespo
    Hirata, Mario Hiroyuki
    EPIGENOMICS, 2024, 16 (11-12) : 809 - 820
12345